Andrea Wang

Andrea Wang is the VP CMC Operations of Curevo Vaccine. She joined Curevo at the beginning of 2022 and has over 20 years of experience in the Biotech industry developing therapeutic drugs including monoclonal antibodies, bispecific antibodies, recombinant protein drugs as well as ADC. Her work has been focused on the CMC development for earlier phase clinical studies as well as commercial drug manufacturing. She also had experience working with QA and RA for cGMP compliance and regulatory applications.

Before joining Curevo, Andrea worked at Aptevo as Senior Director for 3.5 years overseeing product quality and CMC activities for multiple projects. During this time, she played critical roles in obtaining FDA approval for a new dose strength of IXINITY®, specification revision, and drug product shelf-life extension. In addition, she participated in Scientific Advice meetings as a CMC expert and led various activities supporting several clinical-stage programs. Prior to Joining Aptevo, Andrea worked at Silverback, Askgene, Allozyne, and Corixa, and her work span from protein engineering to drug candidate screening/selections, from cGMP production to clinical sample testing. Andrea had 15 peer-reviewed publications, 2 book chapters, and more than 20 patents.